FUNDAMENTALS:
GILD (Gilead Sciences) is that company that found the cure for hepatitis C. The fundamentals are improving again. The industry has not done as well as in others. However, with the recent acquisition of MYR Pharmaceuticals (myr-pharma.com), GILD is currently in phase 3 for the treatment of hepatitis B and D.
TECHNICALS:
Monthly:
wedge pattern and volume divergence tells of that institutions and investors may begin to sponsor this company again.
MACD divergence
Weekly:
regular divergence confirms the case for the monthly pattern
breach to new minor highs within a larger pattern
positive MACD development
volume support
Daily:
Crown pattern
Volume confirmation
Daily horizontal support
Daily wedge pattern being tested and broken
GILD (Gilead Sciences) is that company that found the cure for hepatitis C. The fundamentals are improving again. The industry has not done as well as in others. However, with the recent acquisition of MYR Pharmaceuticals (myr-pharma.com), GILD is currently in phase 3 for the treatment of hepatitis B and D.
TECHNICALS:
Monthly:
wedge pattern and volume divergence tells of that institutions and investors may begin to sponsor this company again.
MACD divergence
Weekly:
regular divergence confirms the case for the monthly pattern
breach to new minor highs within a larger pattern
positive MACD development
volume support
Daily:
Crown pattern
Volume confirmation
Daily horizontal support
Daily wedge pattern being tested and broken
Note
Target: 165
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.